{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:55:16Z","timestamp":1789127716928,"version":"build-2803163510"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health (NIH)","award":["RO1DK118017"],"award-info":[{"award-number":["RO1DK118017"]}]},{"name":"National Institutes of Health (NIH)","award":["3757\/20"],"award-info":[{"award-number":["3757\/20"]}]},{"name":"National Institutes of Health (NIH)","award":["39911\/24"],"award-info":[{"award-number":["39911\/24"]}]},{"name":"Israel Science Foundation (ISF)","award":["RO1DK118017"],"award-info":[{"award-number":["RO1DK118017"]}]},{"name":"Israel Science Foundation (ISF)","award":["3757\/20"],"award-info":[{"award-number":["3757\/20"]}]},{"name":"Israel Science Foundation (ISF)","award":["39911\/24"],"award-info":[{"award-number":["39911\/24"]}]},{"name":"Kaylie Foundation","award":["RO1DK118017"],"award-info":[{"award-number":["RO1DK118017"]}]},{"name":"Kaylie Foundation","award":["3757\/20"],"award-info":[{"award-number":["3757\/20"]}]},{"name":"Kaylie Foundation","award":["39911\/24"],"award-info":[{"award-number":["39911\/24"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>APOL1 Renal Risk Variants (APOL1RRVs, G1, and G2) are known to be toxic to glomerular podocytes and causally associated with an enhanced prevalence and progression of many different etiologies of chronic kidney disease (CKD), leading to the delineation of a new disease designation of APOL1-Mediated Kidney Disease (AMKD). Notably, APOL1RRVs have not consistently been shown to increase the prevalence or severity of diabetic kidney disease (DKD) progression, which is the most common cause of End-Stage Kidney Disease (ESKD). While this apparent discrepancy seems perplexing, its clarification should provide important mechanistic and therapeutic insights. Activation of the Renin\u2013Angiotensin System (RAS) plays a critical role in the development and progression of DKD. Recent in vitro and in vivo studies also demonstrated that RAS activation contributes to kidney cell injury in AMKD experimental models. Both high glucose, as well as APOL1RRVs escalate the podocyte expression of miR193a, a known mediator of glomerulosclerosis, including idiopathic Focal Segmental Glomerular Sclerosis (FSGS) and DKD. We propose that either the RAS and\/or miR193a levels in the diabetic milieu are already maximally conducive to kidney target cell injury and, therefore, are agnostic to further injury in response to APOL1RRVs. Similarly, the contributory role of hypertension (which is frequently reported as the second most common cause of ESKD) in the progression of AMKD remains a controversial issue. Since several clinical reports have shown that controlling hypertension does not consistently slow the progression of AMKD, this has led to a formulation wherein APOL1-RRVs primarily lead to kidney injury with accompanying hypertension. Notably, half a decade later, the notion that hypertension is not a cause but rather a consequence of kidney injury was contested by investigators analyzing the Mount Sinai BioMe repository, a comprehensive clinical and genetic database including participants with APOL1RRVs. These investigators observed that hypertension predated the observed decline in GFR in individuals with APOL1RRVs by ten years. In the present study, we discuss the mechanistic forces that may underpin the gaps in these clinical manifestations, which did not allow the temporal association of hypertension with AMKD to be translated into causation and may also dissociate DKD and AMKD. We have hypothesized models that need to be validated in future experimental studies.<\/jats:p>","DOI":"10.3390\/biom15020205","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:36:32Z","timestamp":1738560992000},"page":"205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["APOL1 Dynamics in Diabetic Kidney Disease and Hypertension"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6898-358X","authenticated-orcid":false,"given":"Pravin C.","family":"Singhal","sequence":"first","affiliation":[{"name":"Department of Medicine, Feinstein Institute for Medical Research, Zucker School of Medicine, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-3406","authenticated-orcid":false,"given":"Karl","family":"Skorecki","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa 3525433, Israel"},{"name":"Department of Nephrology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0272-6386(12)80266-6","article-title":"The familial risk of end-stage renal disease in African Americans","volume":"21","author":"Freedman","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end-stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1681\/ASN.2011060562","article-title":"APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease","volume":"23","author":"Fine","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-016-0735-5","article-title":"Podocytes: The Weakest Link in Diabetic Kidney Disease?","volume":"16","author":"Lin","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Besse, W., Mansour, S., Jatwani, K., Nast, C.C., and Brewster, U.C. (2016). Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: A case report investigation. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0330-7"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1681\/ASN.2020050558","article-title":"AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype","volume":"31","author":"Wu","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41581-020-0332-3","article-title":"COVAN is the new HIVAN: The re-emergence of collapsing glomerulopathy with COVID-19","volume":"16","author":"Velez","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2020060802","article-title":"Kidney Biopsy Findings in Patients with COVID-19","volume":"31","author":"Kudose","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1681\/ASN.2011050519","article-title":"Population-based risk assessment of APOL1 on renal disease","volume":"22","author":"Friedman","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2404211","article-title":"APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans","volume":"392","author":"Gbadegesin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1681\/ASN.2011040388","article-title":"APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-asso-ciated nephropathy","volume":"22","author":"Kopp","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1681\/ASN.2013010113","article-title":"APOL1 variants are associated with increased risk of CKD among African Americans","volume":"24","author":"Foster","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1681\/ASN.2010070730","article-title":"The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans","volume":"21","author":"Freedman","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000353223","article-title":"High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria","volume":"123","author":"Ulasi","year":"2013","journal-title":"Nephron Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/ndt\/gfw451","article-title":"A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy","volume":"33","author":"Skorecki","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.kint.2019.07.010","article-title":"Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background","volume":"96","author":"Lannon","year":"2019","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.kint.2024.03.030","article-title":"Variant upon variant: Kidney-disease risk associated with APOL1 G2 genetic variants is abrogated by the APOL1 p.N264K variant","volume":"106","author":"Madhavan","year":"2024","journal-title":"Kidney Int."},{"key":"ref_20","first-page":"e181238","article-title":"Protein-truncating variant in APOL3 increases chronic kidney disease risk in epistasis with APOL1 risk alleles","volume":"9","author":"Zhang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ekir.2024.04.008","article-title":"Diagnostic Yield of APOL1 p.N264K Variant Screening in Daily Practice","volume":"9","author":"Narjoz","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_22","first-page":"43","article-title":"APOL1 Genotyping Is Incomplete without Testing for the Protective M1 Modifier p.N264K Variant","volume":"4","author":"Gbadegesin","year":"2024","journal-title":"Glomerular Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1038\/s41467-023-43020-9","article-title":"Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease","volume":"14","author":"Gupta","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.085647.108","article-title":"The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions","volume":"19","author":"Smith","year":"2009","journal-title":"Genome Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1006\/geno.2002.6729","article-title":"The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue","volume":"79","author":"Monajemi","year":"2002","journal-title":"Genomics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/geno.2001.6534","article-title":"The human apolipoprotein L gene cluster: Identification, classification, and sites of distribution","volume":"74","author":"Page","year":"2001","journal-title":"Genomics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E2130","DOI":"10.1073\/pnas.1400699111","article-title":"Evolution of the primate trypanolytic factor APOL1","volume":"111","author":"Thomson","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","article-title":"APOL1 and Kidney Disease: From Genetics to Biology","volume":"82","author":"Friedman","year":"2020","journal-title":"Annu. Rev. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)81706-7","article-title":"A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense","volume":"95","author":"Vanhamme","year":"1998","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.micinf.2008.07.020","article-title":"Mutual self-defence: The trypanolytic factor story","volume":"10","author":"Pays","year":"2008","journal-title":"Microbes Infect."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cunningham, P.N., Wang, Z., Grove, M.L., Cooper-DeHoff, R.M., Beitelshees, A.L., Gong, Y., Gums, J.G., Johnson, J.A., Turner, S.T., and Boerwinkle, E. (2019). Hypertensive APOL1, risk allele carriers, demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low-risk carriers. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221957"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jha2.259","article-title":"Effects of Renin-Angiotensin Blockade and APOL1 on Kidney Function in Sickle Cell Disease","volume":"2","author":"Han","year":"2021","journal-title":"eJHaem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mcna.2023.03.004","article-title":"Diabetic Kidney Disease: An Update","volume":"107","author":"Gupta","year":"2023","journal-title":"Med. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"p26","DOI":"10.1159\/000101797","article-title":"Cellular and molecular mechanisms of proteinuria in diabetic nephropathy","volume":"106","author":"Wolf","year":"2007","journal-title":"Nephron Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000325649","article-title":"The renin-angiotensin system","volume":"170","author":"Lai","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/jc.2018-02482","article-title":"JC Viruria Is Associated with Reduced Risk of Diabetic Kidney Disease","volume":"104","author":"Divers","year":"2019","journal-title":"J. Clinl. Endocrinol. Metabol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.kint.2024.07.026","article-title":"Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2","volume":"106","author":"Karreci","year":"2024","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kumar, V., Kaur, P., Ayasolla, K., Jha, A., Wiqas, A., Vashistha, H., Saleem, M.A., Popik, W., Malhotra, A., and Gebeshuber, C.A. (2024). APOL1 Modulates Renin-Angiotensin System. Biomolecules, 14.","DOI":"10.3390\/biom14121575"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00531.2013","article-title":"Renin-angiotensin system within the diabetic podocyte","volume":"308","author":"Riera","year":"2015","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00266.2007","article-title":"Activation of a local renin angiotensin system in podocytes by glucose","volume":"294","author":"Durvasula","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.ki.5002195","article-title":"Activation of the renin-angiotensin system within podocytes in diabetes","volume":"71","author":"Yoo","year":"2007","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1681\/ASN.2014020190","article-title":"MicroRNA-193a Regulates the Transdifferentiation of Human Parietal Epithelial Cells toward a Podocyte Phenotype","volume":"26","author":"Kietzmann","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1681\/ASN.2008070795","article-title":"Recruitment of podocytes from glomerular parietal epithelial cells","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1681\/ASN.2005010055","article-title":"Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene","volume":"16","author":"Wharram","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s10157-024-02465-y","article-title":"Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases","volume":"28","author":"Fukuda","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"F832","DOI":"10.1152\/ajprenal.00541.2017","article-title":"Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu","volume":"314","author":"Mishra","year":"2018","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kumar, V., Paliwal, N., Ayasolla, K., Vashistha, H., Jha, A., Chandel, N., Chowdhary, S., Saleem, M.A., Malhotra, A., and Chander, P.N. (2019). Disruption of APOL1-miR193a Axis Induces Disorganization of Podocyte Actin Cytoskeleton. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-39376-y"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1681\/ASN.2013070687","article-title":"Extensive podocyte loss triggers a rapid parietal epithelial cell response","volume":"25","author":"Hakroush","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.ajpath.2018.07.025","article-title":"Role of Apolipoprotein L1 in Human Parietal Epithelial Cell Transition","volume":"188","author":"Kumar","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nm.3142","article-title":"Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1","volume":"19","author":"Gebeshuber","year":"2013","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0004563220983851","article-title":"Plasma miR-193a-3p can be a potential biomarker for the diagnosis of diabetic nephropathy","volume":"58","author":"Hong","year":"2020","journal-title":"Ann. Clin. Biochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1139\/cjpp-2021-0150","article-title":"miR-193a as a potential mediator of WT-1\/synaptopodin in the renoprotective effect of Losartan on diabetic kidney","volume":"100","author":"Gao","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.2012.369","article-title":"Hypertension-misattributed kidney disease in African Americans","volume":"83","author":"Skorecki","year":"2013","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ki.2012.263","article-title":"Apolipoprotein L1 gene variants are associated with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans","volume":"83","author":"Lipkowitz","year":"2013","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2015.172","article-title":"Hypertension-attributed nephropathy: What\u2019s in a name?","volume":"12","author":"Freedman","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2017.01.040","article-title":"Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans","volume":"69","author":"Nadkarni","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/CIRCRESAHA.124.325305","article-title":"Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ","volume":"135","author":"Yamaguchi","year":"2024","journal-title":"Circ. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/ajh.2009.138","article-title":"Dual blockade of the renin-angiotensin-aldosterone system: Beyond the ACE inhibitor and angiotensin-II receptor blocker combination","volume":"22","author":"Bomback","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yexmp.2017.01.001","article-title":"Vitamin D receptor deficit induces renin-angiotensin system activation via SIRT1 modulation in podocytes","volume":"102","author":"Chandel","year":"2017","journal-title":"Exp. Mol. Patho."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.V971213","article-title":"In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation","volume":"9","author":"Abbate","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ajh.2008.206","article-title":"Effects of renin angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-analysis","volume":"21","author":"Sarafidis","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/dom.14503","article-title":"Sodium\u2013glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation","volume":"23","author":"Moon","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41467-024-55408-2","article-title":"Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease","volume":"16","author":"Zimmerman","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:25Z","timestamp":1760027125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["biom15020205"],"URL":"https:\/\/doi.org\/10.3390\/biom15020205","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}